<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>18(3)</volume><submitter>Koehler C</submitter><funding>European Research Council</funding><funding>VERAXA Biotech GmbH</funding><pubmed_abstract>Due to their target specificity, antibody-drug conjugates─monoclonal antibodies conjugated to a cytotoxic moiety─are efficient therapeutics that can kill malignant cells overexpressing a target gene. Linking an antibody with radioisotopes (radioimmunoconjugates) enables powerful diagnostics and/or closely related therapeutic applications, depending on the isotope. To generate site-specific radioimmunoconjugates, we utilized genetic code expansion and subsequent conjugation by inverse electron-demand Diels-Alder cycloaddition reactions. We show that, using this approach, site-specific labeling of trastuzumab with either zirconium-89 (&lt;sup>89&lt;/sup>Zr) for diagnostics or lutetium-177 (&lt;sup>177&lt;/sup>Lu) for therapeutics yields efficient radioimmunoconjugates. Positron emission tomography imagi</pubmed_abstract><journal>ACS chemical biology</journal><pagination>443-448</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10029752</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Genetic Code Expansion for Site-Specific Labeling of Antibodies with Radioisotopes.</pubmed_title><pmcid>PMC10029752</pmcid><pubmed_authors>Pektor S</pubmed_authors><pubmed_authors>Waldmann C</pubmed_authors><pubmed_authors>Bausbacher N</pubmed_authors><pubmed_authors>Koehler C</pubmed_authors><pubmed_authors>Sauter PF</pubmed_authors><pubmed_authors>Klasen B</pubmed_authors><pubmed_authors>Lemke EA</pubmed_authors><pubmed_authors>Miederer M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Genetic Code Expansion for Site-Specific Labeling of Antibodies with Radioisotopes.</name><description>Due to their target specificity, antibody-drug conjugates─monoclonal antibodies conjugated to a cytotoxic moiety─are efficient therapeutics that can kill malignant cells overexpressing a target gene. Linking an antibody with radioisotopes (radioimmunoconjugates) enables powerful diagnostics and/or closely related therapeutic applications, depending on the isotope. To generate site-specific radioimmunoconjugates, we utilized genetic code expansion and subsequent conjugation by inverse electron-demand Diels-Alder cycloaddition reactions. We show that, using this approach, site-specific labeling of trastuzumab with either zirconium-89 (&lt;sup>89&lt;/sup>Zr) for diagnostics or lutetium-177 (&lt;sup>177&lt;/sup>Lu) for therapeutics yields efficient radioimmunoconjugates. Positron emission tomography imagi</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Mar</publication><modification>2025-04-18T15:29:04.915Z</modification><creation>2025-04-07T02:12:35.555Z</creation></dates><accession>S-EPMC10029752</accession><cross_references><pubmed>36889678</pubmed><doi>10.1021/acschembio.2c00634</doi></cross_references></HashMap>